Respiratory support in European neonatal intensive care units - survey on budesonide addition to surfactant, ventilator settings during invasive ventilation and discharge with caffeine

Respiratory support in European neonatal intensive care units - survey on budesonide addition to surfactant, ventilator settings during invasive ventilation and discharge with caffeine - NICU-VIBE (Neonatologic investigation on caffeine use, ventilation and intratracheal budesonide in Europe)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036534

Enrollment

300

Registered

2025-04-10

Start date

2025-07-17

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

P07

Interventions

Group 1: Only observational/interview group: European neonatologists providing care to patients in the Neonatal Intensive Care Unit (NICU).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Medical practice in a European neonatal intensive care unit (NICU).

Exclusion criteria

Exclusion criteria: Lack of consent to participate in the study. Previous participation in the study.

Design outcomes

Primary

Measure	Time frame
The goal of the project is to collect data on current practices in European neonatal intensive care units (NICUs) in three areas: 1. The use of budesonide with surfactant, 2. Selection of ventilation settings (in particular, inspiratory time), and 3. Therapy with caffeine citrate (especially in the post-discharge setting). From these data, we plan to gain insights concerning the variability in therapeutic approaches among European NICUs and establish a foundation for future clinical trials and potential standardization of patient care in NICUs.	—

Measure

Time frame

The goal of the project is to collect data on current practices in European neonatal intensive care units (NICUs) in three areas: 1. The use of budesonide with surfactant, 2. Selection of ventilation settings (in particular, inspiratory time), and 3. Therapy with caffeine citrate (especially in the post-discharge setting). From these data, we plan to gain insights concerning the variability in therapeutic approaches among European NICUs and establish a foundation for future clinical trials and potential standardization of patient care in NICUs.

—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Albania, Austria, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kosovo, Latvia, Lithuania, Luxembourg, Malta, Moldova, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom

Contacts

Public ContactMartin Kuntz

Universitätsklinikum Freiburg

martin.kuntz@uniklinik-freiburg.de+49 761 27043000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026